Aurora Cannabis partners with UFC on advancing CBD research – MarketWatch

Aurora Cannabis partners with UFC on advancing CBD research - MarketWatch
UFC gets in the octagon with Aurora Cannabis in multi-million dollar partnership
Shares of Aurora Cannabis Inc. ACB, +1.88% rallied 1.5% in premarket trade Tuesday, after the Canada-based cannabis company announced a "multi-year, multi-million dollar" exclusive partnership with UFC to advance research on the relationship between of hemp-derived cannabidiol (CBD) products and athlete wellness and recovery. The research will be conducted at the mixed martial arts organizations performance institute in Las Vegas, with clinical studies to focus on pain management, inflammation, injury/exercise recovery and mental well being. "This global partnership places focus squarely on the health and well-being of UFCs talented and highly trained athletes," said Aurora Chief Executive Terry Booth. "The Aurora-UFC research partnership creates a global platform to launch targeted educational and awareness campaigns, while creating numerous opportunities to accelerate our global CBD business." Auroras stock has soared 71.2% year to date through Monday, while the ETFMG Alternative Harvest ETF MJ, +1.50% has climbed 33.3% and the S&P 500 SPX, +0.86% has gained 13.3%.

Aurora Cannabis Inc. shares rose Tuesday, after the Canadian company said it has entered a multiyear, multimillion-dollar agreement with mixed martial arts organization UFC to research the effect of hemp-derived CBD products on athlete recovery and wellness.

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur, and include, but are not limited to, the completion of the clinical studies by the parties, the subject matter of the clinical studies, and the results of such clinical studies. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release, including, but not limited to the participation of athletes in the clinical studies. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Video: Daily Debate: Whose stock rose the most at UFC Rochester?

The Edmonton-based cannabis producer said it will work with the fight leagues athletes in clinical studies involving pain management, inflammation, injury, exercise recovery, and mental well-being.

Cannabidiol or CBD is a wellness-oriented cannabis compound increasingly being infused into everything from coffee to bath bombs.

In addition to the Companys rapid organic growth and strong execution on strategic M&A, which to date includes 17 wholly owned subsidiary companies – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs, Whistler, and Chemi Pharmaceutical – Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), CTT Pharmaceuticals (OTCC: CTTH), Alcanna Inc. (TSX: CLIQ), High Tide Inc. (CSE: HITI), EnWave Corporation (TSXV: ENW), Capcium Inc. (private), Evio Beauty Group (private), and Wagner Dimas (private).

This global partnership places focus squarely on the health and well-being of UFCs talented and highly trained athletes, Aurora CEO Terry Booth wrote in a news release on Tuesday.

Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high-quality consistent product. Intended to be replicable and scalable globally, our production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs. Each of Auroras facilities is built to meet European Union Good Manufacturing Practices ("EU GMP") standards. Certification has been granted to Auroras first production facility in Mountain View County, the MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland. All Aurora facilities are designed and built to the EU GMP standard.

The Aurora-UFC research partnership creates a global platform to launch targeted educational and awareness campaigns, while creating numerous opportunities to accelerate our global CBD business.

Auroras research will be led by Dr. Jason Dyck, a professor at the University of Alberta and a Canada Research Chair in molecular medicine. He also serves as an independent director on Auroras board.

EDMONTON, May 21, 2019 /PRNewswire/ – Aurora Cannabis Inc. ("Aurora" or the "Company") (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabis worldwide, and UFC®, the worlds premier mixed martial arts organization, are excited to announce an exclusive, multi-year, multi-million dollar, global partnership that is expected to significantly advance further clinical research on the relationship between 100% hemp derived Cannabidiol (CBD) products and athlete wellness and recovery, with a view to accelerating CBD product development and education.

Since the day we opened the Performance Institute, our primary goal was to offer UFC athletes the best possible training, nutrition, and recovery services, UFC President Dana White added in the release.

This partnership with Aurora is an extension of that goal, and were looking forward to collaborating with Aurora to find new ways to improve the health and safety of athletes who compete in UFC.

Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 625,000 kg per annum and sales and operations in 24 countries across five continents, Aurora is one of the worlds largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

The move follows Canopy Growth Corp.s (WEED.TO) partnership with the NHL Alumni Association. Canopy announced in March that it would conduct a double-blind clinical trial involving about 100 former hockey stars aimed at reducing reliance on highly-addictive opioids and other pharmaceutical painkillers.


Posted in Aurora